Alkermes reports positive Phase 1 results for ALKS-2680 in narcolepsy and plans Phase 2 study; Q4 earnings show robust growth ...

Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and ...

Analysts have set 12-month price targets for Alkermes, revealing an average target of $38.0, a high estimate of $50.00, and a ...

The market expects Alkermes (ALKS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in ...

Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKS – Research Report) and Ocular ...

Alkermes (ALKS) reports positive top-line data from a phase Ib, proof-of-concept study investigating ALKS 2680 for the treatment of narcolepsy.

Business & Finance has released the annual Leading in Wellbeing Index, recognising the wellness leaders operating in Ireland ...

Major market player included in this report are: Alkermes plc (Ireland) Allergan, Inc. (Ireland) GlaxoSmithKline plc (UK) Mylan N.V.(US) The objective of the study is to define market sizes of ...

Chris Shibutani, an analyst from Goldman Sachs, maintained the Hold rating on Organon (OGN – Research Report). The associated price ...